690 related articles for article (PubMed ID: 22782416)
41. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Klinkenbijl JH; Jeekel J; Sahmoud T; van Pel R; Couvreur ML; Veenhof CH; Arnaud JP; Gonzalez DG; de Wit LT; Hennipman A; Wils J
Ann Surg; 1999 Dec; 230(6):776-82; discussion 782-4. PubMed ID: 10615932
[TBL] [Abstract][Full Text] [Related]
42. Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater.
Schiergens TS; Reu S; Neumann J; Renz BW; Niess H; Boeck S; Heinemann V; Bruns CJ; Jauch KW; Kleespies A
Surgery; 2015 Jul; 158(1):151-61. PubMed ID: 25819575
[TBL] [Abstract][Full Text] [Related]
43. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
Takada T; Amano H; Yasuda H; Nimura Y; Matsushiro T; Kato H; Nagakawa T; Nakayama T;
Cancer; 2002 Oct; 95(8):1685-95. PubMed ID: 12365016
[TBL] [Abstract][Full Text] [Related]
44. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Reni M; Cordio S; Milandri C; Passoni P; Bonetto E; Oliani C; Luppi G; Nicoletti R; Galli L; Bordonaro R; Passardi A; Zerbi A; Balzano G; Aldrighetti L; Staudacher C; Villa E; Di Carlo V
Lancet Oncol; 2005 Jun; 6(6):369-76. PubMed ID: 15925814
[TBL] [Abstract][Full Text] [Related]
45. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Dahan L; Bonnetain F; Ychou M; Mitry E; Gasmi M; Raoul JL; Cattan S; Phelip JM; Hammel P; Chauffert B; Michel P; Legoux JL; Rougier P; Bedenne L; Seitz JF;
Gut; 2010 Nov; 59(11):1527-34. PubMed ID: 20947887
[TBL] [Abstract][Full Text] [Related]
46. Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma.
Acharya A; Markar SR; Sodergren MH; Malietzis G; Darzi A; Athanasiou T; Khan AZ
Br J Surg; 2017 Jun; 104(7):814-822. PubMed ID: 28518410
[TBL] [Abstract][Full Text] [Related]
47. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
[TBL] [Abstract][Full Text] [Related]
48. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.
Yeo CJ; Cameron JL; Lillemoe KD; Sohn TA; Campbell KA; Sauter PK; Coleman J; Abrams RA; Hruban RH
Ann Surg; 2002 Sep; 236(3):355-66; discussion 366-8. PubMed ID: 12192322
[TBL] [Abstract][Full Text] [Related]
49. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
50. Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot study.
Splinter TA; Obertop H; Kok TC; Jeekel J
J Cancer Res Clin Oncol; 1989; 115(2):200-2. PubMed ID: 2715169
[TBL] [Abstract][Full Text] [Related]
51. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
Krishnan S; Rana V; Evans DB; Varadhachary G; Das P; Bhatia S; Delclos ME; Janjan NA; Wolff RA; Crane CH; Pisters PW
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):735-43. PubMed ID: 17980502
[TBL] [Abstract][Full Text] [Related]
52. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
53. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
54. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Khorana AA; Mangu PB; Berlin J; Engebretson A; Hong TS; Maitra A; Mohile SG; Mumber M; Schulick R; Shapiro M; Urba S; Zeh HJ; Katz MHG
J Clin Oncol; 2017 Jul; 35(20):2324-2328. PubMed ID: 28398845
[TBL] [Abstract][Full Text] [Related]
55. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
56. Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Aitini E; Marangolo M
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):51-7. PubMed ID: 16767907
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Cantore M; Serio G; Pederzoli P; Mambrini A; Iacono C; Pulica C; Capelli P; Lombardi M; Torri T; Pacetti P; Pagani M; Fiorentini G
Cancer Chemother Pharmacol; 2006 Oct; 58(4):504-8. PubMed ID: 16633830
[TBL] [Abstract][Full Text] [Related]
58. Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis.
Kang J; Lee W; Shin J; Park Y; Kwon JW; Jun E; Song KB; Lee JH; Hwang DW; Park SY; Kim SC
Langenbecks Arch Surg; 2022 May; 407(3):1091-1097. PubMed ID: 35013798
[TBL] [Abstract][Full Text] [Related]
59. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
Zaghloul MS; Christodouleas JP; Smith A; Abdallah A; William H; Khaled HM; Hwang WT; Baumann BC
JAMA Surg; 2018 Jan; 153(1):e174591. PubMed ID: 29188298
[TBL] [Abstract][Full Text] [Related]
60. Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
Kim HS; Shin SJ; Kim JH; Kim H; Choi HJ
Tohoku J Exp Med; 2013 Sep; 231(1):21-8. PubMed ID: 23994910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
